Company profile
ALTERITY THERAPEUTICS LTD
NASDAQ:ATHEBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PBT-434 | phase2 | — | 2 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05864365 | phase2 | completed | 2023-05-23 | 2025-02-26 | Alterity Therapeutics | A Biomarker Study of ATH434 in Participants With MSA |
| NCT07729852 | phase2 | enrolling_by_invitation | 2026-10-01 | 2029-07-01 | Alterity Therapeutics | Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France |
| NCT05109091 | phase2 | completed | 2022-07-01 | 2024-11-28 | Alterity Therapeutics | Study of ATH434 in Participants with Multiple System Atrophy |
FDA applications (0)
No records yet.